Abbott Vascular's XIENCE V Everolimus-Eluting Coronary is indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions (up to 28 mm long) with reference vessel diameter of 2.5 to 4.09 mm.
October 31, 2023 — SMT (Sahajanand Medical Technologies), a leading medical device company in India, focused on ...
October 31, 2023 
October 10, 2023 — Elixir Medical, a developer of innovative cardiovascular technologies, announced it will present ...
October 10, 2023 
July 13, 2023 — Elixir Medical, a developer of breakthrough cardiovascular technologies, announced enrollment completion ...
July 13, 2023 
July 12, 2023 — In a late breaking trial session during EuroPCR 2023 in Paris, on behalf of the HOST-IDEA study ...
July 12, 2023 
May 25, 2023 — First-generation bioresorbable vascular scaffolds (BVS) may be just as effective as drug-eluting metallic ...
May 25, 2023 
January 2, 2023 — The U.S. Food and Drug Administration (FDA) has approved the BioFreedom Drug Coated Coronary Stent ...
January 02, 2023 
December 23, 2022 — According to Coherent Market Insights, the global Drug Eluting Stents market is estimated to be ...
December 23, 2022 
June 2, 2022 — Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, announced print ...
June 02, 2022 
February 16, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, has announced ...
February 16, 2022 
January 26, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Boston Scientific's Synergy Megatron Drug ...
January 26, 2021